HSPA4

Heat shock 70 kDa protein 4 · P34932 · HSPA4 on Sugi Atlas →

0 patent compounds predicted against HSPA4, 0 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours

Clinical trials — most relevant to HSPA4 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
OGX-427 in Castration Resistant Prostate Cancer Patients PHASE2COMPLETED
Gemcitabine, Docetaxel, and Hydroxychloroquine in Treating Participants With Recurrent or Refractory Osteosarcoma PHASE1/PHASE2ACTIVE_NOT_RECRUITING
Melpida: Recombinant Adeno-associated Virus (serotype 9) Encoding a Codon Optimized Human AP4M1 Transgene (hAP4M1opt) PHASE1/PHASE2RECRUITING
17AAG to Treat Kidney Tumors in Von Hippel-Lindau Disease PHASE2COMPLETED
Targeting Endoplasmic Reticulum Stress in Human Hypertension PHASE1/PHASE2RECRUITING
Phase 1/ Phase 2 Study to Assess Safety and Efficacy of Orally Administered JBI-802 in Subjects With Myeloproliferative Neoplasms (MPN) and Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN) With Thrombocytosis PHASE1/PHASE2RECRUITING
Study of Oral CNF2024 (BIIB021) in Advanced Solid Tumors PHASE1COMPLETED
Safety and Pharmacology of SNX-5422 Plus Carboplatin and Paclitaxel in Subjects With Solid Tumors PHASE1COMPLETED
HS-201, an HSP90 Inhibitor-linked Verteporfin for Detection of Solid Malignancies PHASE1WITHDRAWN
SNX-5422 to Treat Solid Tumor Cancers and Lymphomas PHASE1COMPLETED
Safety and Pharmacology Study of SNX-5422 in Subjects With Resistant Lung Adenocarcinoma PHASE1COMPLETED
17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Solid Tumors That Cannot Be Removed By Surgery PHASE1COMPLETED
Safety Study of IPI-504 in Patients With Relapsed and Relapsed Refractory Multiple Myeloma PHASE1COMPLETED
PBA Use for Treatment of ATF6-/- Patients EARLY_PHASE1SUSPENDED
Exercise on Expression of Heat Shock Protein 70 in Arterial Risk nanCOMPLETED
Hereditary Spastic Paraplegia Genomic Sequencing Initiative (HSPseq) nanRECRUITING
Perfusion-Induced Hyperthermia for Metastatic Carcinoma nanCOMPLETED
LncRNA Nicotinamide Nucleotide Transhydrogenase-Antisense RNA1 NNT-AS1 in CRC nanCOMPLETED
Registry and Natural History Study for Early Onset Hereditary Spastic Paraplegia nanRECRUITING
BASE HSP110 : A New Therapeutic Target and a New Marker for Prognosis of Type MSI Colorectal Cancer nanUNKNOWN
Acute Passive Heating in Healthy Older Adults nanCOMPLETED
Cardioprotective Benefit of Passive Heat Therapy in Higher-Level Spinal Cord Injury: Safety and Proof of Concept nanUNKNOWN
The Role of HSP90 in Peripheral Vascular Lesions of Diabetic Atherosclerosis nanCOMPLETED
Chronic Heat Therapy for Improving Vascular Health nanCOMPLETED
Trial of Nonsurgical Treatment of Intermittent Claudication Due to Femoro-popliteal Disease nanCOMPLETED
Possible Diagnostic Protein Markers in Schistosoma Related Bladder Diseases. nanNOT_YET_RECRUITING
Reduced Ventilator-Free Days and Bacterial Colonization of Sub-Glottic Secretions nanWITHDRAWN
Establishment of Human Cellular Disease Models for Wilson Disease nanCOMPLETED
Role of Sorcin and Annexin A3 in Breast Cancer Patients nanUNKNOWN
Spastic Paraplegia - Centers of Excellence Research Network nanRECRUITING

Related proteins — ESM-2 sequence neighbours (a HSPA4 binder may also engage these)

ProteinNameSimilarity
Q61316 1.000 Q61316 →
Q5RDM4 1.000 Q5RDM4 →
O88600 1.000 O88600 →
Q2TFN9 1.000 Q2TFN9 →
HSPA4L Heat shock 70 kDa protein 4L 0.994 landscape →
P48722 0.992 P48722 →
Q5R606 0.984 Q5R606 →
HSPH1 Heat shock protein 105 kDa 0.981 landscape →
Q0IIM3 0.980 Q0IIM3 →
Q61699 0.978 Q61699 →
Q66HA8 0.977 Q66HA8 →
Q60446 0.972 Q60446 →
PIK3R1 Phosphatidylinositol 3-kinase regulatory subunit alpha 0.954 landscape →
Q9QW07 0.954 Q9QW07 →
A0FKG7 0.953 A0FKG7 →
Q9Z1F9 0.953 Q9Z1F9 →
RNGTT mRNA-capping enzyme 0.953 landscape →
Q84M92 0.953 Q84M92 →
Q63787 0.953 Q63787 →
TPP2 Tripeptidyl-peptidase 2 0.952 landscape →
Q7ZWS1 0.952 Q7ZWS1 →
Q28DS0 0.952 Q28DS0 →
Q64514 0.952 Q64514 →
Q5R8R4 0.952 Q5R8R4 →
O60879 0.952 O60879 →
P23727 0.951 P23727 →
A2YR10 0.951 A2YR10 →
Q6ZJW9 0.951 Q6ZJW9 →
Q9SV21 0.950 Q9SV21 →
UBA2 SUMO-activating enzyme subunit 2 0.950 landscape →